Equity Profile

FMS

Fresenius Medical Care AG

Health CareHealth Care Services$11.8B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026After Close9:00 AM EDT

Company Snapshot

Fresenius Medical Care AG is a leading provider of products and services for individuals with renal diseases. Operating in the health care sector, the company focuses on dialysis services and related products, making it a key player in the growing health care services industry.

Key Metrics to Watch

EPS

Earnings per share is a crucial measure of profitability, and investors will be keen to see if Fresenius can meet or exceed expectations this quarter.

$0.50

Revenue

Revenue growth indicates the company's ability to expand its services and customer base, which is vital for long-term success.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius reported an EPS of $0.17, missing estimates by 6.74%. The stock reacted negatively, declining by 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Fresenius to report an EPS of $0.50 and revenue of $4.6 billion for Q1 2026. The market is looking for signs of recovery after a disappointing previous quarter.

Bull Case

If Fresenius can exceed the EPS estimate and show strong revenue growth, it may indicate a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its operational efficiency and long-term growth prospects.

Key Metrics to Watch

EPS

$0.50

Earnings per share is a crucial measure of profitability, and investors will be keen to see if Fresenius can meet or exceed expectations this quarter.

Revenue

$4.6B

Revenue growth indicates the company's ability to expand its services and customer base, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Fresenius achieve an EPS of at least $0.50?

This figure is critical as it reflects the company's profitability and ability to meet market expectations after a prior miss.

What are the revenue growth trends in the dialysis segment?

Understanding revenue growth will provide insight into the company's market position and demand for its services.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth in the dialysis segment, as recent market trends indicate increasing demand for renal care services.

Supporting Evidence

Historical data shows that Fresenius has often rebounded strongly after misses, suggesting resilience.

Options pricing indicates a higher expected move than historical averages, hinting at potential volatility that could favor a positive outcome.

Key Risk

If revenue growth in the dialysis segment exceeds expectations, it could significantly alter the market's perception of Fresenius.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny due to a prior earnings miss, making it crucial for Fresenius to demonstrate recovery.

Bull Confirmed If

An EPS of $0.53 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.47 would raise serious concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests the stock could rise by around 2.7% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors assess management's commentary.

Miss

A miss could lead to a decline of approximately 1.2% based on historical patterns, raising concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the dialysis segment.
2Insights on cost management strategies and their impact on margins.
3Details on patient growth and retention rates in their service centers.
4Comments on competitive pressures and market share trends.
5Management's outlook on future earnings and revenue guidance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a crucial measure of profitability, and investors will be keen to see if Fresenius can meet or exceed expectations this quarter.

$0.50

Revenue

Revenue growth indicates the company's ability to expand its services and customer base, which is vital for long-term success.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius reported an EPS of $0.17, missing estimates by 6.74%. The stock reacted negatively, declining by 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Fresenius to report an EPS of $0.50 and revenue of $4.6 billion for Q1 2026. The market is looking for signs of recovery after a disappointing previous quarter.

Bull Case

If Fresenius can exceed the EPS estimate and show strong revenue growth, it may indicate a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its operational efficiency and long-term growth prospects.

Key Metrics to Watch

EPS

$0.50

Earnings per share is a crucial measure of profitability, and investors will be keen to see if Fresenius can meet or exceed expectations this quarter.

Revenue

$4.6B

Revenue growth indicates the company's ability to expand its services and customer base, which is vital for long-term success.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Fresenius achieve an EPS of at least $0.50?

This figure is critical as it reflects the company's profitability and ability to meet market expectations after a prior miss.

What are the revenue growth trends in the dialysis segment?

Understanding revenue growth will provide insight into the company's market position and demand for its services.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth in the dialysis segment, as recent market trends indicate increasing demand for renal care services.

Supporting Evidence

Historical data shows that Fresenius has often rebounded strongly after misses, suggesting resilience.

Options pricing indicates a higher expected move than historical averages, hinting at potential volatility that could favor a positive outcome.

Key Risk

If revenue growth in the dialysis segment exceeds expectations, it could significantly alter the market's perception of Fresenius.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny due to a prior earnings miss, making it crucial for Fresenius to demonstrate recovery.

Bull Confirmed If

An EPS of $0.53 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.47 would raise serious concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests the stock could rise by around 2.7% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors assess management's commentary.

Miss

A miss could lead to a decline of approximately 1.2% based on historical patterns, raising concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the dialysis segment.
2Insights on cost management strategies and their impact on margins.
3Details on patient growth and retention rates in their service centers.
4Comments on competitive pressures and market share trends.
5Management's outlook on future earnings and revenue guidance.